Altre lingue XTL Biopharmaceuticals Ltd. Nasdaq

Azioni

XTLB

US98386D3070

Mercato chiuso - Nasdaq Altri mercati azionari 21:59:52 15/05/2024			Variaz. 5gg	Var. 1 gen.
2,74 ^USD	+6,61%		+11,84%	+171,26%

30/04	XTL Biopharmaceuticals Ltd. Riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
29/04	I migliori guadagni del mercato premarket	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
Top Premarket Gainers	29/04
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	02/04
XTL Biopharmaceuticals : Immediate Report of Meeting	21/03
XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K	21/03
XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding	20/03
Top Midday Gainers	20/03
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	20/03
XTL To Aquire The Social Proxy	20/03
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.	20/03
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	15/11
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	15/11
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	20/10/23
XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)	25/08/21
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors	03/08/17
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors	27/04/17
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	05/04/17
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer	04/04/17
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	30/03/17
XTL Biopharmaceuticals Ltd. announced that it has received $2.8 million in funding	22/03/17

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue XTL Biopharmaceuticals Ltd. Nasdaq

Azioni

XTLB

US98386D3070

Altre lingue

Filtri